CSU spinoff VetDC raises $2.1M to help commercialize canine cancer drug

FORT COLLINS – Colorado State University spinoff VetDC Inc. has raised $2.1 million of what it hopes will be a total round of $3 million to $6 million to help move its canine lymphoma drug toward commercialization.

Chairman and chief financial officer Steve Warnecke said Tuesday that $3 million would allow the Fort Collins-based company to build inventory, finish the Food and Drug Administration approval process, and launch Tanovea.

The drug would be five-year-old VetDC’s first to market, though it has others in the development pipeline that also treat cancer in animals. VetDC filed for FDA approval of Tanovea in January. Warnecke…